Company intelligence / Profile preview
HypoSpray Pharma
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
No commercialized drugs; proprietary transdermal platform demonstrated clinical equivalence for various drugs. Ongoing collaborations to deliver both small molecules and biologics including monoclonal antibodies, with clinical data supporting serum exposure, rapid absorption, and functional outcomes in pre-clinical and early clinical studies. In oncology, partnered programs are entering Phase 1 with external sponsors.
- Therapeutic areas
- ImmunologyNeurologyEndocrinologyOncology
- Modalities
- Small moleculeBiologicMonoclonal antibodyPeptides
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on HypoSpray Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HypoSpray Pharma.